Verve Therapeutics

VERVE THERAPEUTICS INC

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

CRSP

VERV

CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.

CRISPR Therapeutics&#39; Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

Display,Of,Stock,Market,Quotes

Intraday Update

Markets

BEAM

CLSK

ERAS

MVST

NTLA

PCRX

QURE

RCKT

REPL

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday

Netflix

EOSE

ERIC

FRGE

LEGN

NFLX

NMAX

RKLB

RZLV

Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday (CORRECTED)

Verve Therapeutics Inc

MGI MEDIA & GAMES INVEST by MGI MEDIA & GAMES INVEST SE

Verve Group SE

Press Releases

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

Management

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

ABOS

CLYM

LENZ

SLDB

Abivax

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Celcuity

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

CEL-SCI

Emergent BioSolutions

Erasca

Humacyte

Inventiva S.A. - American Depository Shares

Inventiva

Jade Biosciences

MeiraGTx Hldgs

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Myriad Genetics

Organogenesis Holdings

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

Sage Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tourmaline Bio

Verastem

Guggenheim

Canaccord Genuity

HC Wainwright & Co.

RBC Capital

Stifel

Comments

Verve Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell